Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Apr 21, 2023; 29(15): 2322-2335
Published online Apr 21, 2023. doi: 10.3748/wjg.v29.i15.2322
Table 1 Comparison of demographic and medical records in the study groups, n (%)
Variable
Group I (n = 105)
Group II (n = 175)
Group III (n = 139)
Group IV (n = 86)
F/χ2
P
Demographics
Age (yr)66.20 ± 7.9367.94 ± 7.4167.74 ± 7.8468.00 ± 7.861.3440.259
Male 65 (61.9)95 (54.3)82 (59.0)56 (65.1)3.304 0.347
Smokers 29 (27.6)49 (28.0)51 (36.7)32 (37.2)4.697 0.195
Body-mass index (kg/m2)23.11 ± 2.3723.23 ± 3.9523.75 ± 3.2424.27 ± 3.522.5200.057
Medical history
Hypertension 20 (19.0)32 (18.3)35 (25.2)26 (30.2)6.041 0.110
Hyperlipidemia 20 (19.0)50 (28.6)68 (48.9)40 (46.5)31.658 < 0.001
Diabetes mellitus23 (21.9)35 (20.0)37 (26.6)26 (30.2)4.146 0.246
Atrial fibrillation8 (7.6)36 (20.6)52 (37.4)34 (39.5)38.947< 0.001
Stroke3 (2.9)5 (2.9)4 (2.9)4 (4.7)0.90810.864
Cirrhosis etiology
Fatty liver17 (16.2)22 (12.6)17 (12.2)17 (19.8)3.2770.351
Alcoholic liver18 (17.1)38 (21.7)32 (23)26 (30.2)4.7480.191
Viral hepatitis53 (50.5)100 (57.1)75 (54)36 (41.9)5.6950.127
Autoimmune liver disease16 (15.2)15 (8.6)14 (10.1)9 (10.5)3.1570.368
Liver cancer5 (4.8)8 (4.6)7 (5)4 (4.7)0.15111.000
Table 2 Comparison of clinical data among groups, n (%)
Variable
Group I (n = 105)
Group II (n = 175)
Group III (n = 139)
Group IV (n = 86)
F/χ2
P
Clinical feature
Haematemesis6 (5.7)12 (6.9)16 (11.5)16 (18.6)11.588 0.009
Edema2 (1.9)12 (6.9)20 (14.4)33 (38.4)65.284 < 0.001
SBP 1 (1.0)4 (2.3)11 (7.9)13 (15.1)23.486 < 0.001
Hyponatremia 3 (2.9)21 (12.0)31 (22.3)31 (36.0)42.806 < 0.001
Hepatic encephalopathy5 (4.8)10 (5.7)14 (10.1)19 (22.1)21.565 < 0.001
Refractory ascites2 (1.9)4 (2.3)15 (10.8)21 (24.4)44.367 < 0.001
Jaundice 12 (11.4)13 (7.4)15 (10.8)20 (23.3)14.120 0.003
MELD score8.74 ± 1.548.64 ± 1.5717.04 ± 1.96a,b25.19 ± 2.15a,b,c2081.425< 0.001
Laboratory index
RDW (%)12.54 ± 0.8513.29 ± 1.19a14.3 ± 1.96a,b16.25 ± 2.13a,b,c101.958< 0.001
TBIL (μmol/L)12.3 (10.9, 13.45)11.5 (9.8, 14.5)12.8 (10.7, 17.5)b16.3 (13.18,24.95)a,b,c57.344< 0.001
ALB (g/L)45.91 ± 3.8344.92 ± 5.19a37.85 ± 4.71a,b33.50 ± 5.65a,b,c159.072< 0.001
ALT (IU/L)24 (18, 32)27 (21, 34)a32 (23, 37)a,b35 (26, 75)a,b,c40.591< 0.001
AST (IU/L)26 (19.5, 33)28 (21, 35)30 (22, 36)a34 (25, 62)a,b25.257< 0.001
γ-GT (IU/L)32 (20, 44)30 (22, 41)35 (26, 43)37 (26, 47)a,b14.960.002
ALP (IU/L)65 (52, 84)74 (53, 88)69 (54, 87)69 (58, 84)3.5350.316
WBC count (× 109/L)5.64 ± 1.515.36 ± 1.405.76 ± 1.16b6.10 ± 1.55a,b5.6950.001
Hemoglobin (g/L)122.86 ± 15.53121.10 ± 15.30107.92 ± 16.33a,b99.28 ± 18.15a,b,c52.186< 0.001
Platelet count (× 109/L)190.15 ± 62.47174.98 ± 41.71a101.09 ± 27.46a,b90.38 ± 32.33a,b165.715< 0.001
INR0.91 (0.59, 1.27)1.21 (0.61, 1.80)a1.58 (0.86, 2.41)a,b1.37 (1.17, 2.22)a,b57.797< 0.001
NT-proBNP (pg/mL)72 (61, 84)76 (61, 98)354 (127, 653)a,b647 (364, 1430)a,b,c242.974< 0.001
eGFR (ml/min/1.73 m2)62.35 ± 11.0960.87 ± 13.5259.07 ± 15.9443.31 ± 11.39a,b,c40.691< 0.001
Drug information
Diuretic 3 (2.9)7 (4)20 (14.4)32 (37.2)69.996 < 0.001
Spirolactone 3 (2.9)7 (4)17 (12.2)26 (30.2)50.491 < 0.001
ACEI/ARB 7 (6.7)23 (13.1)22 (15.8)23 (26.7)15.690 0.001
β-blocker 6 (5.7)13 (7.4)23 (16.5)22 (25.6)23.776 < 0.001
Table 3 Multiple logistics regression analysis for each group and the control group
Part
Variable
B
SE
Wald
P
OR (95%Cl)
Part IRDW (%)0.7770.17320.141 < 0.0012.175 (1.549, 3.054)
TBIL (μmol/L)-0.0860.0512.810 0.094 0.918 (0.83, 1.015)
ALB (g/L)-0.0600.0352.973 0.085 0.942 (0.879, 1.008)
ALT (IU/L)0.1220.0673.350 0.067 1.129 (0.991, 1.287)
AST (IU/L)-0.1080.0603.178 0.075 0.898 (0.798, 1.011)
γ-GT (IU/L)0.0040.0110.117 0.733 1.004 (0.982, 1.026)
WBC count (× 109/L)0.0260.1070.059 0.808 1.026 (0.832, 1.265)
Hemoglobin (g/L)0.0120.0101.294 0.255 1.012 (0.992, 1.032)
Platelet count (× 109/L)-0.0060.0033.638 0.056 0.994 (0.988, 1.000)
INR0.4180.2902.074 0.150 1.519 (0.86, 2.683)
NT-proBNP (pg/mL)0.0010.0020.417 0.518 1.001 (0.997, 1.005)
eGFR (mL/min/1.73 m2)-0.0090.0120.598 0.439 0.991 (0.967, 1.015)
Hyperlipidemia-0.074 0.346 0.046 0.831 0.929 (0.471, 1.830)
Atrial fibrillation-0.402 0.602 0.448 0.503 0.669 (0.206, 2.174)
Haematemesis-0.730 0.711 1.054 0.305 0.482 (0.12, 1.942)
Edema0.105 1.196 0.008 0.930 1.111 (0.107, 11.580)
SBP1.623 2.242 0.524 0.469 5.07 (0.063, 410.934)
Hyponatremia-1.682 0.934 3.243 0.072 0.186 (0.030, 1.16)
Hepatic encephalopathy-0.161 0.804 0.040 0.842 0.852 (0.176, 4.119)
Jaundice-1.044 1.264 0.683 0.409 0.352 (0.030, 4.188)
Refractory ascites0.256 1.498 0.029 0.864 1.292 (0.069, 24.324)
Part IIRDW (%)0.895 0.294 9.265 0.002 2.447 (1.375, 4.354)
TBIL (μmol/L)-0.028 0.083 0.116 0.733 0.972 (0.825, 1.145)
ALB (g/L)-0.723 0.140 26.552 < 0.0010.485 (0.369, 0.639)
ALT (IU/L)0.337 0.087 15.167 < 0.0011.401 (1.182, 1.660)
AST (IU/L)-0.390 0.087 19.883 < 0.0010.677 (0.571, 0.804)
γ-GT (IU/L)0.037 0.018 4.313 0.038 1.037 (1.002, 1.074)
WBC count (× 109/L)0.592 0.253 5.464 0.019 1.807 (1.100, 2.969)
Hemoglobin (g/L)-0.057 0.026 4.929 0.026 0.944 (0.898, 0.993)
Platelet count (× 109/L)-0.055 0.010 32.104 < 0.0010.947 (0.929, 0.965)
INR1.894 0.563 11.321 0.001 6.643 (2.205, 20.018)
NT-proBNP (pg/mL)0.008 0.003 8.203 0.004 1.008 (1.003, 1.014)
eGFR (mL/min/1.73 m2)0.062 0.027 5.365 0.021 1.064 (1.010, 1.121)
Hyperlipidemia-1.173 0.658 3.174 0.075 0.309 (0.085, 1.125)
Atrial fibrillation0.365 1.006 0.132 0.717 1.441 (0.201, 10.345)
Haematemesis2.282 1.499 2.318 0.128 9.792 (0.519, 184.678)
Edema3.004 1.778 2.855 0.091 20.159 (0.618, 657.095)
SBP4.715 4.750 0.985 0.321 111.572 (0.010, 1231574.165)
Hyponatremia-0.424 1.259 0.113 0.736 0.655 (0.055, 7.724)
Hepatic encephalopathy-1.850 1.290 2.057 0.151 0.157 (0.013, 1.970)
Jaundice1.862 2.392 0.606 0.436 6.437 (0.059, 699.588)
Refractory ascites-1.431 3.819 0.140 0.708 0.239 (0, 425.671)
Part IIIRDW (%)1.582 0.341 21.541 < 0.0014.863 (2.493, 9.483)
TBIL (μmol/L)-0.080 0.090 0.787 0.375 0.923 (0.774, 1.101)
ALB (g/L)-0.910 0.150 37.020 < 0.0010.402 (0.300, 0.539)
ALT (IU/L)0.350 0.087 16.273 < 0.0011.419 (1.197, 1.682)
AST (IU/L)-0.410 0.088 21.725 < 0.0010.664 (0.559, 0.789)
γ-GT (IU/L)0.032 0.018 3.226 0.072 1.033 (0.997, 1.070)
WBC count (× 109/L)0.763 0.292 6.798 0.009 2.144 (1.208, 3.803)
Hemoglobin (g/L)-0.070 0.029 5.697 0.017 0.932 (0.880, 0.988)
Platelet count (× 109/L)-0.077 0.013 35.070 < 0.0010.926 (0.902, 0.950)
INR1.828 0.621 8.661 0.003 6.224 (1.842, 21.031)
NT-proBNP (pg/mL)0.008 0.003 7.937 0.005 1.008 (1.002, 1.014)
eGFR (mL/min/1.73 m2)-0.005 0.033 0.018 0.892 0.995 (0.932, 1.063)
Hyperlipidemia-0.404 0.764 0.280 0.5970.667 (0.149, 2.986)
Atrial fibrillation0.417 1.132 0.135 0.7131.517 (0.165, 13.954)
Haematemesis3.164 1.693 3.493 0.06223.67 (0.857, 653.530)
Edema3.826 1.882 4.132 0.04245.891 (1.147, 1836.043)
SBP5.570 4.815 1.339 0.247262.503 (0.021, 3291299.144)
Hyponatremia-0.376 1.364 0.076 0.7830.687 (0.047, 9.940)
Hepatic encephalopathy-1.949 1.468 1.763 0.1840.142 (0.008, 2.530)
Jaundice0.527 2.529 0.043 0.8351.694 (0.012, 240.821)
Refractory ascites-0.538 3.896 0.019 0.8900.584 (0, 1210.714)
Table 4 Pearson correlation analysis between red blood cell distribution width and each index

Child-Pugh score
MELD score
NT-proBNP
RDWr value0.6420.5920.715
P value< 0.001< 0.001< 0.001
Table 5 Receiver operating characteristic curve analysis of key indexes among groups
Variable
AUC (95%Cl)
SE
P
Critical value
Sensitivity
Specificity
Youden index
RDW0.686 (0.624, 0.748)0.032< 0.00113.0556.0%71.4%0.274
NTproBNP 0.556 (0.490, 0.623)0.0340.11495.5028.0%89.5%0.175